Saint Luke’s Cancer Institute

The team at Saint Luke’s Cancer Institute provides early detection, expert diagnosis, personalized treatment options, and survivorship support to every patient. It’s what Saint Luke’s calls precision medicine: the right treatment for the right patient at the right time.

We offer the region’s only precision oncology program for advanced cancers that’s staffed by clinical oncologists with expertise in genomic sequencing and computational biology. With our clinical trial agreement with the internationally recognized Washington University School of Medicine, we can offer more than 200 National Cancer Institute-sponsored clinical trials and industry-led studies to Saint Luke’s Cancer Institute patients.

Personalized Cancer Treatment

Saint Luke’s Cancer Institute offers options for patients at every stage in their cancer journey:

• Medical oncologists and hematologists who subspecialize in every type of cancer, including breast, lung, gastrointestinal, liver, brain, gynecologic and colon
• Genomic sequencing and precision oncology services for advanced cancers
• A Multidisciplinary Breast Clinic where patients meet with a team of specialists in one comprehensive appointment
• The region’s largest network of 3-D mammography centers for early detection of the smallest tumors
• Nurse navigators who serve as patient resources and advocates through treatment and beyond
• Innovative surgeries for brain tumors
• Supportive Oncology and Rehabilitative Services program to help patients overcome the physical and emotional challenges that often follow diagnosis and treatment
• Radiation Oncology offering leading-edge technology at four convenient metro locations

Second Opinions

When it comes to potentially life-changing or lifesaving treatments, patients and their families often seek a second opinion. Second opinions can provide:

• Confirmation of a diagnosis
• More details about type of cancer and stage, which affect treatment options
• Perspective from subspecialized oncologists

If you started your cancer journey at another facility, the experts at Saint Luke’s Cancer Institute are available to review your records and provide a thoughtful second opinion, including personalized treatment options available at Saint Luke’s.

Classes and Events

• Gilda’s Club Kansas City
• Look Good Feel Better
• Breast Cancer Support Groups
• Nutrition for Cancer Survivorship 
• Dr. Jeffrey Wieman Cancer Prevention Lecture Series 

View all classes and events.

Clinical Trials Available at Saint Luke's

For more information about clinical trials at Saint Luke's Cancer Institute, call 816-932-2677.

Advanced Solid Tumor

• EAY131 Molecular Analysis for Therapy Choice (MATCH)
  Learn more
• A Prospective Registry Study to Evaluate the Efficacy of Personalized Medicine on Advanced Solid Tumors

Brain

• BMX-HGG-001: A phase 1/2 trial for patients with newly diagnosed high grade glioma treated with concurrent radiation therapy, temozolomide and BMX-001
  Learn more
• Orbus STELLAR: Phase 3, randomized, open-label study to evaluate the efficacy and safety of Eflornithine with lomustine compared to lomustine alone in patients with anaplastic astrocytoma that progress/recur after irradiation and adjuvant temozolomide chemotherapy
  Learn more

Breast Cancer

• A011502 Aspirin in Preventing Recurrence of Cancer in Patients with Her2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery and/or Radiation Therapy
  Learn more
• Development and Implementation of The Breast Cancer Collaborative Registry (BCCR)
  Learn more
• A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
  Learn more
• Novartis - Ribociclib with endocrine therapy in the adjuvant tx of HR-positive, Her2 negative early breast cancer (NATALEE) (Mel / Kelley)
  Learn more
• SGNTUC-025-A single arm, open label phase 2 study of tucatinib in combination with trastuzumab deruxtecan in subjects with previously treated unresectable locally-advanced or metastatic Her2+ breast cancer
  Learn more
• EFC15935 A randomized, multicenter, double-blind phase 3 study of SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER+, HER2- breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease
  Learn more
• Sermonix ESR1 SMX 18001 An Open, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Postmenopausal Women with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation
  Learn more
• Sanofi ACT16105 ACT16105: Phase 2 study of SAR439859 vs physician's choice in premenopausal and postmenopausal localled advanced or metastatic ER-positive breast cancer
  Learn more
• H3 Biomedical A101: Phase II multicenter, open-label trial of H3B-6545, a covalent antagonist of estrogen receptor alpha, inwomen with locally advanced or metastatic estrogen receptor-positive, Her2 negative breast cancer
• H3B-6545-G000-102 An Open Label multicenter phase 1b study of H3B-6545 in combination with palbociclib in women with advanced or metastatic estrogen receptor positive Her2 negative breast cancer
  Learn more
• A Multi-center, Open-label, Phase 2 Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DHP107 (Liporaxel®, Oral Paclitaxel) Compared to IV Paclitaxel in Patients With Recurrent or Metastatic Breast Cancer(OPERA)
  Learn more
• Seattle Genetics SGNTUC-016 Seattle Genetics Phase 3 clinical trial of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally advanced or metastatic HER2+ breast cancer (SGNTUC-016)
  Learn more
• A Compassionate use study of leronlimab (PRO140) plus treatment of physician's choice in patients with CCR5+ metastatic triple-negative breast cancer
  Learn more
• A011401 Breast Cancer Weight Loss Study (BWEL Study): Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
  Learn more
• Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination With Pembrolizumab for First-Line Treatment of Patients With Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
  Learn more

GI

• A021703 Randomized double-blind Phase III trial of Vitamin D3 supplementation in patients with previously untreated metastatic colorectal cancer (SOLARIS)
  Learn more
• A221805-Duloxetine to prevent oxaliplatin-induced chemo-induced peripheral neuropathy: randomized double blind placebo-controlled phase II to Phase III study
  Learn more
• BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer
  Learn more

GI (Pancreatic)

• FibroGen LAPIS Phase 3 Clinical Trial - Study of Pamrevlumab in Combination With Chemotherapy as Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer
  Learn more
• EA2186 A randomized phase II study of gemcitabine and nab-paclitaxel copared with 5-FU, leucovorin, and liposomal irinotecan in older patients with treatment naive metastatic pancreatic cancer (GIANT)
  Learn more

GU (Urothelial)

• A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab, or With Standard of Care Chemotherapy, Versus Standard of Care Chemotherapy in Participants With Previously Untreated Unresectable or Metastatic Urothelial Cancer (CheckMate901)
  Learn more

Hematology

• A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)
  Learn more

Lung Cancer

• Pacific 4: Phase III, Randomized, Placebo-controlled, double-blind, multi-center, international study of durvalumab following stereotactic body radiation therapy (SBRT) for the treatment of patients with unresected Stage I/II, lymph node-negative NSCLC
  Learn more
• Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
  Learn more
• Randomized Study of Erlotinib vs. Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
  Learn more
• A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
  Learn more
• Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
  Learn more
• Lunar: Pivotal randomized, open-label study of tumor treating fields (TT Fields) concurrent with standard of care therapies for treatment of stage 4 NSCLC patients, following progression while on or after platinum-based treatment  
  Learn more
• Lung Map: Master Protocol for Treatment of Non-Small Cell Lung Cancer
  Learn more
• S1900A A phase II study of Rucaparib in patients with genomic LOH high and/or deleterious BRCA 1/2 mutation stage IV non-small cell lung cancer
  Learn more
• S1900B A Phase II study of Selpercatinib (LOXO-292) in patients with RET fusion-positive stage IV or recurrent non-small cell lung cancer
  Learn more
• S1900C A phase II study of Talazoparib plus Avelumab in patients with Stage IV or recurrent non-squamous non-small cell lung cancer-bearing pathogenic STK11 genomic alterations (lung-map sub-study)
  Learn more
• S1800A: A phase II randomized study of Ramucirumab Plus MK3475 (Pembrolizumab) versus standard of care for patients previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer (lung-map non-matched sub-study)
  Learn more

View the Saint Luke's Cancer Institute 2019 Annual Report (PDF).